The latest market report published by Credence Research, Inc. “Global Non-Hodgkin Lymphoma Therapeutics Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028. The global non-hodgkin lymphoma therapeutics market has witnessed steady growth in recent years and is expected to continue growing at a CAGR of 8.80% between 2023 and 2030. The market was valued at USD 8.5 billion in 2022 and is expected to reach USD 15.34 billion in 2030.
The global non-Hodgkin lymphoma (NHL) therapeutics market is expected to experience substantial growth in the coming years, driven by key factors such as the rising incidence of non-Hodgkin lymphoma, the expansion of potential pipeline medications, high diagnostic rates, and a susceptible pediatric population.
The report highlights that radiation therapy is currently the most popular type of therapy, accounting for over 43% of the market share in terms of value in 2022. However, the chemotherapy segment is expected to exhibit the fastest CAGR during the forecast period. Among cell types, B-cell lymphomas dominate the global demand for non-Hodgkin lymphoma therapeutics, holding a substantial share of over 80% in 2022 and projected to grow at a rapid CAGR.
Geographically, North America leads the global market growth, contributing to over one-third of the market share in 2022. The region’s dominance is attributed to the high prevalence of various cancers, including non-Hodgkin lymphoma, as well as advanced diagnostic and treatment options. Asia Pacific and Europe collectively account for just under 50% of the market share, with Europe holding over 22% in 2022.
The Non-Hodgkin Lymphoma Therapeutics Market Key Growth Trends are driving the development of innovative therapies to combat this complex and heterogeneous disease. With advancements in precision medicine, there is a growing focus on targeted therapies that specifically address the underlying genetic abnormalities associated with non-Hodgkin lymphoma subtypes. Additionally, immunotherapy approaches such as immune checkpoint inhibitors and CAR-T cell therapy have shown promising results in clinical trials, offering new hope for patients with refractory or relapsed disease. Another key trend is the emergence of combination therapies, which aim to enhance treatment efficacy by targeting multiple pathways simultaneously. Furthermore, the advent of biosimilars has contributed to increased accessibility and affordability of biologic drugs used in non-Hodgkin lymphoma treatment regimens.
Leading players in the global non-Hodgkin lymphoma therapeutics market include AstraZeneca PLC, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, Seattle Genetics, Teva Pharmaceuticals, Takeda Pharmaceutical Company Limited, Spectrum Pharmaceuticals Inc., and Janssen Pharmaceuticals Inc. These companies are focused on product innovation, expanding their distribution channels, and strategic collaborations to maintain a competitive edge.
Why to Buy This Report-
- The report provides a qualitative as well as quantitative analysis of the global Non-Hodgkin Lymphoma Therapeutics Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.
- The report includes information on the competitive landscape, such as how the market’s top competitors operate at the global, regional, and country levels.
- Major nations in each region with their import/export statistics
- The global Non-Hodgkin Lymphoma Therapeutics Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.
Browse Full Report: https://www.credenceresearch.com/report/non-hodgkin-lymphoma-therapeutics-market